Table 1.
Relationship of gender, diseases, and medications of patients with the magnitude of the contractile force of atrial samples (measured at the end of the wash-out period after the third adenosine concentration-response curve), and with the magnitude of the response to isoproterenol (ISO).
| Contractile Force (Direct + Indirect; n = 22) | p | Response to ISO (Indirect; n = 12) | p | |||
|---|---|---|---|---|---|---|
| Small (n = 13) % | Large (n = 9) % | Weak (n = 5) % | Strong (n = 7) % | |||
| Gender (female) | 15.4 | 22.2 | >0.99 | 0 | 14.3 | >0.99 |
| Diseases | ||||||
| DM | 46.2 | 33.3 | 0.67 | 0 | 57.1 | 0.08 |
| Hyperlipidemia | 46.2 | 44.4 | >0.99 | 40 | 57.1 | >0.99 |
| Ischemia | 84.6 | 77.8 | >0.99 | 40 | 85.7 | 0.22 |
| Hypertension | 69.2 | 77.8 | >0.99 | 20 | 85.7 | 0.07 |
| Heart failure | 46.2 | 33.3 | 0.67 | 20 | 71.4 | 0.24 |
| VHD | 46.2 | 33.3 | 0.67 | 20 | 57.1 | 0.29 |
| Drugs | ||||||
| Antiplatelets | 76.9 | 66.7 | 0.66 | 60 | 42.9 | >0.99 |
| Anticoagulants | 38.5 | 33.3 | >0.99 | 42.9 | 14.3 | 0.56 |
| β-blockers | 84.6 | 100 | 0.49 | 100 | 71.4 | 0.47 |
| ACEI | 61.5 | 88.9 | 0.33 | 60 | 71.4 | >0.99 |
| Ca2+ channel b. | 15.4 | 22.2 | >0.99 | 20 | 14.3 | >0.99 |
| NO donors | 15.4 | 44.4 | 0.18 | 0 | 14.3 | >0.99 |
| Diuretics | 46.2 | 66.7 | 0.41 | 40 | 57.1 | >0.99 |
| Trimetazidine | 15.4 | 44.4 | 0.18 | 0 | 28.6 | 0.47 |
| Statins | 76.9 | 66.7 | 0.66 | 40 | 57.1 | >0.99 |
| Insulin | 15.4 | 11.1 | >0.99 | 0 | 28.6 | 0.47 |
| Oral antidiab. | 30.8 | 22.2 | >0.99 | 28.6 | 0 | 0.47 |
| PPI | 69.2 | 44.4 | 0.38 | 100 | 57.1 | 0.2 |
| Potassium | 23.1 | 22.2 | >0.99 | 20 | 28.6 | >0.99 |
| Benzodiazep. | 15.4 | 22.2 | >0.99 | 20 | 14.3 | >0.99 |
| Allopurinol | 7.7 | 22.2 | 0.54 | 0 | 14.3 | >0.99 |
The percentage occurrence of patients with a given condition regarding the contractile force and the response to ISO, with the related level of statistical significance, are indicated. Small: small contractile force; Large: large contractile force; Weak: weak positive inotropic response to ISO; Strong: strong positive inotropic response to ISO; Direct: Direct group; Indirect: Indirect group; DM: diabetes mellitus (both types); Ischemia: chronic ischemic heart disease, angina pectoris, myocardial infarction (with or without ST-elevation), ischemic cardiomyopathy; Heart failure: cardiac decompensation, congestive heart failure, dilated cardiomyopathy; VHD: valvular heart disease; ACEI: angiotensin-converting enzyme inhibitors; Ca2+ channel b.: blockers of the L-type calcium channel; NO donors: compounds that provide nitric oxide in the body (e.g., nitrites and nitrates); Oral antidiab.: orally active antidiabetic drugs; PPI: proton-pump inhibitors; Benzodiazep.: benzodiazepines.